Table 4. Treatment-emergent adverse events occurring in ≥2 volunteers in any group (safety population).

	Denosumab 60 mg (N = 23)	Denosumab 120 mg (N = 23)	Placebo (N = 17)
Any adverse event, n (%)	18 (78)	19 (83)	11 (65)
Decrease in blood calcium levels	13 (57)	13 (57)	1 (6)
Increase in blood calcium levels	1 (4)	2 (9)	1 (6)
Alanine aminotransferase increased	1 (4)	2 (9)	0
Upper respiratory tract infection	8 (35)	6 (26)	3 (18)
Diarrhea	2 (9)	3 (13)	1 (6)
Abdominal pain	2 (9)	0	1 (6)
Pain in extremity	0	2 (9)	2 (12)
Contusion	0	2 (9)	0